Dual-acting receptor antagonist
Links shared publicly online about this topic.
- 2,051total visits
Dual-acting receptor antagonist
View full resource at theheart.org
Tags: Heart Disease, High Blood Pressure, High Blood Pressure Medication, Avapro, Aprovel, Avalide
Most Recently Shared on May 11, 2009 at 5:45 pm By:
heartwire: Dual-acting receptor antagonist superior to ARB for treatment of hypertension http://bit.ly/1hOOu
Results from Merck's vorapaxar study on cardiovascular events
news-medical.net — “Researchers today presented and published results from the TRA-2P (Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) TIMI 50 study of vorapaxar, Merck's investigational anti-thrombotic medicine, in patients with a prior history of cardiovascular events or disease.” View full resource at news-medical.net
Most Recently Shared on March 26, 2012 at 11:02 am By:
Tom Heston, MD Doctor, Family Medicine Doctor, and Physician
Results from Merck's vorapaxar study on cardiovascular events - http://t.co/hYnpGrbr http://t.co/bBoZlApT #health
ACC: Events Cut, but Bleeding Up with Novel Drug (CME/CE) - QualityPoint Technologies
qualitypointtech.net — “CHICAGO (MedPage Today) -- An investigational thrombin receptor antagonist -- vorapaxar -- reduced ischemic events in patients with stable atherosclerotic disease but increased bleeding, a large randomized trial showed.” View full resource at qualitypointtech.net
Most Recently Shared on March 24, 2012 at 4:00 pm By:
ACC: Events Cut, but Bleeding Up with Novel Drug (CME/CE): CHICAGO (MedPage Today) -- An investigational thrombin ... http://t.co/n25Q8wTy
Novel Antiplatelet Agent Reduces CV Events But Increases Bleeding - Forbes
forbes.com — “Vorapaxar, the novel antiplatelet agent from Merck, appears to effectively reduce cardiovascular death and ischemic events in patients with MI, ischemic stroke, or peripheral vascular disease, but its potential utility is clouded by bleeding complications, including intracranial hemorrhage. Results from the TRA 2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of [...]” View full resource at forbes.com
Most Recently Shared on March 24, 2012 at 2:07 pm By:
Drugs and Devices OW OW Health
Novel Antiplatelet Agent Reduces CV Events But Increases Bleeding: Vorapaxar, the novel antiplatelet agent... http://t.co/UiSxUrWH #drug
The CB1 Receptor Antagonist, AM281, Improves Recognition Loss Induced by Naloxone in Morphine Withdrawal Mice - Vaseghi - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library
onlinelibrary.wiley.com — “The CB1 Receptor Antagonist, AM281, Improves Recognition Loss Induced by Naloxone in Morphine Withdrawal Mice - Vaseghi - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on March 20, 2012 at 4:49 am By:
Drugs and Devices OW OW Health
The CB1 Receptor Antagonist, AM281, Improves Recognition Loss Induced by Naloxone in Morphine Withdrawal Mice: A... http://t.co/lwpOhO27
Histamine H2-receptor antagonists... [Cochrane Database Syst Rev. 2012] - PubMed - NCBI
ncbi.nlm.nih.gov — “PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on March 20, 2012 at 3:28 am By:
John Weiner Allergist, Physician, Doctor, and Internist
Often used in Australia @JuanCIvancevich Cochrane Review Histamine H2 antagonists for urticaria http://t.co/oHl2L6MG
Comparison of inhaled corticosteroids and leukotriene receptor antagonists in adolescents and adults with mild-moderate asthma: a meta-analysis - Yang - The Clinical Respiratory Journal - Wiley Online Library
onlinelibrary.wiley.com — “Comparison of inhaled corticosteroids and leukotriene receptor antagonists in adolescents and adults with mild-moderate asthma: a meta-analysis - Yang - The Clinical Respiratory Journal - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on February 28, 2012 at 11:10 am By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Comparison of inhaled corticosteroids and leukotriene receptor antagonists in adolescents and adults with asthma... http://t.co/ihYFJI2u
Fingolimod in Multiple Sclerosis | Now@NEJM
blogs.nejm.org — “In the latest article in our Clinical Therapeutics review series, Fingolimod for Multiple Sclerosis, a 37-year-old man with multiple sclerosis has recurrent” View full resource at blogs.nejm.org
Most Recently Shared on January 28, 2012 at 9:10 pm By:
Ves Dimov, M.D. Internist, Allergist, Physician, and Doctor
Fingolimod in Multiple Sclerosis - it works by binding to S1P receptors and acting as highly potent antagonist http://t.co/1YTWJnV5
ACTEMRA (tocilizumab) | Rheumatoid Arthritis Treatment
actemra.com — “Find information about ACTEMRA, an FDA-approved treatment for rheumatoid arthritis. ACTEMRA is a prescription medicine called an interleukin-6 (IL-6) receptor inhibitor. ACTEMRA is used to treat adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a Tumor Necrosis Factor (TNF) antagonist has been used and did not work well. ACTEMRA is used to treat people with active systemic juvenile idiopathic arthritis (SJIA) 2 years of age and older. So” View full resource at actemra.com
Most Recently Shared on January 20, 2012 at 3:35 pm By:
FDA Approves Cetuximab for Late-Stage Head and Neck Cancer | Oral Cancer News
oralcancernews.org — “FDA Approves Cetuximab for Late-Stage Head and Neck Cancer | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 9, 2011 at 1:05 pm By:
Low-Dose Naltrexone: The Benefits of This Prescription Drug
articles.mercola.com — “Low-dose naltrexone or LDN, a prescription drug classified as an opioid antagonist, blocks opioid receptors and helps activate your body's immune system.” View full resource at articles.mercola.com
Most Recently Shared on September 20, 2011 at 1:15 am By:
Dr. Mercola Doctor, Family Medicine Doctor, and Physician
One of the RARE #Drugs that Actually Helps Your Body to Heal Itself. http://ow.ly/6w3Si
Leukotriene receptor antagonists as first line or add-on treatment for asthma -- Ducharme 343 -- bmj.com
bmj.com — “Leukotriene receptor antagonists as first line or add-on treatment for asthma -- Ducharme 343 -- bmj.com” View full resource at bmj.com
Most Recently Shared on September 16, 2011 at 12:44 pm By:
Juan C. Ivancevich, MD Doctor, Internist, Allergist, and Physician
Leukotriene receptor antagonists as first line or add-on treatment for asthma http://t.co/3eeUlG9o
Urology Article | Ureter
mdlinx.com — “Comparing efficacy of alpah-1D-receptor antagonist naftopidil and alpha-1A/D-receptor antagonist tamsulosin in management of distal ureteral stones” View full resource at mdlinx.com
Most Recently Shared on September 11, 2011 at 8:00 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Comparing efficacy of alpah-1D-receptor antagonist naftopidil and alpha-1A/D-receptor antagonist tamsul... http://t.co/qrTz8Ys #urology
How does Tamoxifen actually work?
healthtap.com — “Some breast cancer cells have receptors on them that bind to estrogen in order to grow. Tamoxifen acts as an "antagonist" and blocks estrogen from binding to these receptors on the cancer cells by binding to them first. With Tamoxifen sitting in estrogen's place, the cancer cell can no longer grow.” View full resource at healthtap.com
Most Recently Shared on September 6, 2011 at 4:02 am By:
Michael A. Zadeh, M.D. Physician, Doctor, and Surgeon
#HealthTap: How does Tamoxifen actually work? Answer http://t.co/WrBDIVG
Low-dose naltrexone (LDN): Tricking the body to heal itself
sciencedaily.com — “Researchers have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN) can suppress cell proliferative-related disorders such as cancer and autoimmune diseases. LDN causes a compensatory increase in an endogenous opioid, the opioid growth factor (OGF, [Met5]-enkephalin), and the OGF receptor (OGFr).” View full resource at sciencedaily.com
Most Recently Shared on September 3, 2011 at 5:05 pm By:
Paul Abramson MD Doctor, Active Health Library, CAM, Family Medicine Doctor, Integrative Physician, and Physician
Low-dose #naltrexone: tricking the body to heal itself? http://t.co/dmytJCE via @sciencedaily
Brain cannabinoid CB2 receptors modulate cocaine's actions in mice : Nature Neuroscience : Nature Publishing Group
nature.com — “Although small molecules that act on cannabinoid CB1 receptor are known to modulate cocaine seeking behavior in rodents, the role of type 2 cannabinoid receptor (CB2R) in drug of abuse-related behavior is less clear. Here, Xi and colleagues demonstrate that a selective CB2R antagonist inhibits cocaine self-administration in mice by acting through central CB2Rs in the nucleus accumbens.” View full resource at nature.com
Most Recently Shared on August 31, 2011 at 11:32 pm By:
Jafri Malin Abdullah Physician, PhD, Doctor, Surgeon, and Neurosurgeon
Does Kratom do the same?:http://t.co/Qt3sZbM
Advertisement
